Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Hot Flashes 1Cushing Syndrome 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Non-small Cell Lung Cancer 1

Interventions

zopiclone 1N,N'-(1,4-phenylenebis(methylene))dipyrimidin-2-amine 1Moxifloxacin 1Mannose-Binding Lectin 1Esomeprazole 1Dabigatran 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hot Flashes × Dabigatran × Clear all
NCT05471817 2022-11-22

A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants

Bayer

Phase 1 Completed
20 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 1, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡